Left Atrial Appendage Occlusion and Post-procedural Antithrombotic Management

Anders Kramer; Giuseppe Patti; Jens Erik Nielsen-Kudsk; Sergio Berti; Kasper Korsholm

doi:10.3390/jcm13030803

Left Atrial Appendage Occlusion and Post-procedural Antithrombotic Management

Anders Kramer, Giuseppe Patti, Jens Erik Nielsen-Kudsk, Sergio Berti, Kasper Korsholm

Department of Clinical Medicine - The Department of Cardiological Medicine B

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

Abstract

Left atrial appendage occlusion (LAAO) is an established alternative to oral anticoagulation for stroke prevention in atrial fibrillation. Antithrombotic therapy is used in the post-procedural period to prevent device-related thrombosis (DRT). The risk of DRT is considered highest in the first 45-90 days after device implantation, based on animal studies of the device healing process. Clinically applied antithrombotic regimens vary greatly across studies, continents, and centers. This article gives an overview of the evidence behind current antithrombotic regimens, ongoing randomized trials, and future post-procedural management.

Original language	English
Article number	803
Journal	Journal of Clinical Medicine
Volume	13
Issue	3
ISSN	2077-0383
DOIs	https://doi.org/10.3390/jcm13030803
Publication status	Published - Jan 2024

Keywords

anticoagulation
antiplatelet
atrial fibrillation
ischemic stroke
left atrial appendage occlusion

Access to Document

10.3390/jcm13030803Licence: CC BY

Device-Related Thrombosis in Left Atrial Appendage Occlusion
Kramer, A. D. (PI), Korsholm, K. K. (PI), Nielsen-Kudsk, J. E. (PI) & Alkhouli, M. (Collaborator)
01/02/2021 → 30/05/2024
Project: Research

Cite this

@article{2943f175aee34d778dbef5db24aa5506,

title = "Left Atrial Appendage Occlusion and Post-procedural Antithrombotic Management",

abstract = "Left atrial appendage occlusion (LAAO) is an established alternative to oral anticoagulation for stroke prevention in atrial fibrillation. Antithrombotic therapy is used in the post-procedural period to prevent device-related thrombosis (DRT). The risk of DRT is considered highest in the first 45-90 days after device implantation, based on animal studies of the device healing process. Clinically applied antithrombotic regimens vary greatly across studies, continents, and centers. This article gives an overview of the evidence behind current antithrombotic regimens, ongoing randomized trials, and future post-procedural management.",

keywords = "anticoagulation, antiplatelet, atrial fibrillation, ischemic stroke, left atrial appendage occlusion",

author = "Anders Kramer and Giuseppe Patti and Nielsen-Kudsk, {Jens Erik} and Sergio Berti and Kasper Korsholm",

year = "2024",

month = jan,

doi = "10.3390/jcm13030803",

language = "English",

volume = "13",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

publisher = "MDPI AG",

number = "3",

}

TY - JOUR

T1 - Left Atrial Appendage Occlusion and Post-procedural Antithrombotic Management

AU - Kramer, Anders

AU - Patti, Giuseppe

AU - Nielsen-Kudsk, Jens Erik

AU - Berti, Sergio

AU - Korsholm, Kasper

PY - 2024/1

Y1 - 2024/1

N2 - Left atrial appendage occlusion (LAAO) is an established alternative to oral anticoagulation for stroke prevention in atrial fibrillation. Antithrombotic therapy is used in the post-procedural period to prevent device-related thrombosis (DRT). The risk of DRT is considered highest in the first 45-90 days after device implantation, based on animal studies of the device healing process. Clinically applied antithrombotic regimens vary greatly across studies, continents, and centers. This article gives an overview of the evidence behind current antithrombotic regimens, ongoing randomized trials, and future post-procedural management.

AB - Left atrial appendage occlusion (LAAO) is an established alternative to oral anticoagulation for stroke prevention in atrial fibrillation. Antithrombotic therapy is used in the post-procedural period to prevent device-related thrombosis (DRT). The risk of DRT is considered highest in the first 45-90 days after device implantation, based on animal studies of the device healing process. Clinically applied antithrombotic regimens vary greatly across studies, continents, and centers. This article gives an overview of the evidence behind current antithrombotic regimens, ongoing randomized trials, and future post-procedural management.

KW - anticoagulation

KW - antiplatelet

KW - atrial fibrillation

KW - ischemic stroke

KW - left atrial appendage occlusion

U2 - 10.3390/jcm13030803

DO - 10.3390/jcm13030803

M3 - Review

C2 - 38337496

SN - 2077-0383

VL - 13

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 3

M1 - 803

ER -

Left Atrial Appendage Occlusion and Post-procedural Antithrombotic Management

Abstract

Keywords

Access to Document

Fingerprint

Projects

Device-Related Thrombosis in Left Atrial Appendage Occlusion

Cite this